An analysis compares Abbott Labs and Johnson & Johnson, evaluating which 'Dividend King' stock presents a better buying opportunity for investors.

An analysis explores whether investors should consider buying Abbott Labs stock aggressively before July 16, providing insights into its potential performance.

A dividend roundup report highlights declarations from companies including AGNC Investments, Abbott Labs, and AbbVie, among others.

TD Cowen has increased its stock price target for Abbott Laboratories, citing strong growth in the company's cancer diagnostics segment as the primary driver for the upgrade.

Financial commentator Jim Cramer has provided a range of stock recommendations, advising on whether to buy, hold, or avoid various companies including TJX, Caterpillar, Eli Lilly, and Cloudflare. He also expressed regret over selling Cisco and cautioned against buying certain stocks at their current highs.

An article analyzes Abbott Labs as a dividend-paying company, suggesting it could be a profitable long-term investment.

This article evaluates Abbott Labs and Glaukos, two prominent healthcare stocks, to determine which offers a superior investment opportunity for the year 2026.

Several stocks are making notable movements in midday trading, with companies like Abbott Labs, AMD, Charles Schwab, and On Semi among those headlining the market.